AstraZeneca (AZ) has announced that its immunotherapy Imfinzi (durvalumab) has been approved by the European Commission (EC) ...

Independent Advisor Alliance increased its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.0% in the fourth ...

IMFINZITM (durvalumab) has received approval in the European Union as a monotherapy for treating adults with limited-stage ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers ...

We recently published a list of 10 Best European Stocks to Buy According to Billionaires. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

Wealthfront Advisers LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange ...

Astra will buy EsoBiotec for up to £770m comprised of an initial £327m payment and another £443m in the future if it hits ...

The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based ...

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...